Korea United Pharm Inc. (CEO Kang Duk-young) announced on the 29th that it held an oncology treatment seminar, inviting key medical personnel from Vietnam and the Philippines with the support of KOTRA. This seminar, attended by medical professionals from both countries, was made possible through long-established local partnerships.

On the 26th, the company invited key partners and prescribing doctors from Vietnam and the Philippines to the Seoul Royal Hotel to introduce the efficacy and clinical value of its oral anticancer drugs under the theme "Rediscovery of Traditional Cancer Treatment: Oral Anticancer Drugs."

The seminar featured Professor Lee Joon-ho from Chung-Ang University Hospital as a speaker, with attendees including representatives from Vietnamese partner Duoc Dai Nam, Philippine partner Qualimed, and local medical professionals.

Duoc Dai Nam is a specialized anticancer drug distributor in Vietnam, with the National Cancer Hospital as a major client. Qualimed, a partner since 1999, supplies Korea United Pharm's anticancer drugs throughout the Philippines.

The presentation focused on Korea United Pharm's oral anticancer drugs, Methotrexate (product name: Unitrexate Tab) and Hydroxyurea (product name: Hydrine Caps), explaining their mechanisms and characteristics. Methotrexate is an antimetabolite anticancer drug that inhibits folic acid metabolism to prevent cancer cell growth, while Hydroxyurea is an oral anticancer drug that inhibits DNA synthesis.

The seminar shared clinical application cases and overseas prescription experiences of these drugs. Key discussion points included the convenience of administration and the quality of life improvements for patients, which are advantages of oral anticancer drugs.

Both Vietnam and the Philippines are experiencing an increasing trend in cancer incidence due to aging populations and lifestyle changes. Vietnam sees a continuous rise in annual cancer patients, and the Philippines faces a similar situation. Consequently, there is growing demand for accessible cancer treatment methods in both countries.

Korea United Pharm has been collaborating with local partners in the Vietnamese market since the early 2000s and in the Philippine market since 1999. Through these long-term partnerships, the company has built trust with local medical professionals and continues to engage in ongoing academic exchanges.

The company currently supplies anticancer drugs to major medical institutions, including the National Cancer Hospital in Vietnam, through Duoc Dai Nam. In the Philippines, it has established a distribution system to supply products to medical institutions nationwide through Qualimed.

Interest in oral anticancer drugs is rising in both countries due to their ease of administration compared to injectable anticancer drugs, allowing patients to maintain their daily lives while receiving treatment.

A representative from Korea United Pharm stated, "This invitation seminar was more than just a product promotion; it was an event where partner companies with long-standing trust relationships and medical experts from various generations came together. We plan to continue our efforts to expand into overseas markets and provide cancer treatment methods that can benefit patients worldwide."

Popular News